Immunotherapies Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapies stocks.

Immunotherapies Stocks Recent News

Date Stock Title
Nov 21 PYXS Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade
Nov 20 PYXS Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset
Nov 20 PYXS Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
Nov 20 GDTC Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
Nov 20 HCWB HCW Biologics prices $6.9M registered direct offering at $1.03 per share
Nov 19 GOVX GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
Nov 19 IMCR Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode
Nov 19 HCWB HCW Biologics announces pricing of $6.9M registered direct offering, concurrent private placement
Nov 19 HCWB HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
Nov 18 HCWB Top Midday Gainers
Nov 18 HCWB Why Is Penny Stock HCW Biologics Surging On Monday?
Nov 18 IMCR Is Immunocore Holdings plc (IMCR) the Best Immunotherapy Stock to Buy Now?
Nov 18 HCWB HCW Biologics jumps on license agreement for immunotherapeutic product candidate
Nov 18 HCWB HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
Nov 16 SLS We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
Nov 15 HCWB HCW Biologics reports Q3 results
Nov 15 SABS These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts
Nov 14 HCWB HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
Immunotherapies

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags